Decreased intestinal CYP3A in celiac disease: reversal after successful gluten-free diet: a potential source of interindividual variability in first-pass drug metabolism

Chim C. Lang; R. Michael Brown; Mark T. Kinirons; Mary-Ann Deathridge; F. Peter Guengerich; Dermot Kelleher; D. Sean O'Briain; Fayez K. Ghishan; Alastair J. J. Wood

doi:10.1016/S0009-9236(96)90022-3

Decreased intestinal CYP3A in celiac disease: reversal after successful gluten-free diet: a potential source of interindividual variability in first-pass drug metabolism

Chim C. Lang, R. Michael Brown, Mark T. Kinirons, Mary-Ann Deathridge, F. Peter Guengerich, Dermot Kelleher, D. Sean O'Briain, Fayez K. Ghishan, Alastair J. J. Wood

Research output: Contribution to journal › Article › peer-review

58 Citations (Scopus)

Abstract

Cytochrome P450 (CYP) 3A is constitutively expressed in human intestinal villi and may account for significant "first-pass" prehepatic metabolism of a number of drugs in the intestine. Celiac disease results in small intestinal atrophy. We hypothesized that this would result in a loss of CYP3A.

Original language	English
Pages (from-to)	41-46
Number of pages	6
Journal	Clinical Pharmacology & Therapeutics
Volume	59
Issue number	1
DOIs	https://doi.org/10.1016/S0009-9236(96)90022-3
Publication status	Published - 1996

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0009-9236(96)90022-3

Cite this

Lang, C. C., Brown, R. M., Kinirons, M. T., Deathridge, M.-A., Guengerich, F. P., Kelleher, D., O'Briain, D. S., Ghishan, F. K., & Wood, A. J. J. (1996). Decreased intestinal CYP3A in celiac disease: reversal after successful gluten-free diet: a potential source of interindividual variability in first-pass drug metabolism. Clinical Pharmacology & Therapeutics, 59(1), 41-46. https://doi.org/10.1016/S0009-9236(96)90022-3

@article{b3de1e88df5a4804bead883e71526b3c,

title = "Decreased intestinal CYP3A in celiac disease: reversal after successful gluten-free diet: a potential source of interindividual variability in first-pass drug metabolism",

abstract = "Cytochrome P450 (CYP) 3A is constitutively expressed in human intestinal villi and may account for significant {"}first-pass{"} prehepatic metabolism of a number of drugs in the intestine. Celiac disease results in small intestinal atrophy. We hypothesized that this would result in a loss of CYP3A.",

author = "Lang, {Chim C.} and Brown, {R. Michael} and Kinirons, {Mark T.} and Mary-Ann Deathridge and Guengerich, {F. Peter} and Dermot Kelleher and O'Briain, {D. Sean} and Ghishan, {Fayez K.} and Wood, {Alastair J. J.}",

year = "1996",

doi = "10.1016/S0009-9236(96)90022-3",

language = "English",

volume = "59",

pages = "41--46",

journal = "Clinical Pharmacology & Therapeutics",

issn = "0009-9236",

publisher = "Wiley",

number = "1",

}

Lang, CC, Brown, RM, Kinirons, MT, Deathridge, M-A, Guengerich, FP, Kelleher, D, O'Briain, DS, Ghishan, FK & Wood, AJJ 1996, 'Decreased intestinal CYP3A in celiac disease: reversal after successful gluten-free diet: a potential source of interindividual variability in first-pass drug metabolism', Clinical Pharmacology & Therapeutics, vol. 59, no. 1, pp. 41-46. https://doi.org/10.1016/S0009-9236(96)90022-3

Decreased intestinal CYP3A in celiac disease: reversal after successful gluten-free diet: a potential source of interindividual variability in first-pass drug metabolism. / Lang, Chim C.; Brown, R. Michael; Kinirons, Mark T. et al.
In: Clinical Pharmacology & Therapeutics, Vol. 59, No. 1, 1996, p. 41-46.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Decreased intestinal CYP3A in celiac disease

T2 - reversal after successful gluten-free diet: a potential source of interindividual variability in first-pass drug metabolism

AU - Lang, Chim C.

AU - Brown, R. Michael

AU - Kinirons, Mark T.

AU - Deathridge, Mary-Ann

AU - Guengerich, F. Peter

AU - Kelleher, Dermot

AU - O'Briain, D. Sean

AU - Ghishan, Fayez K.

AU - Wood, Alastair J. J.

PY - 1996

Y1 - 1996

N2 - Cytochrome P450 (CYP) 3A is constitutively expressed in human intestinal villi and may account for significant "first-pass" prehepatic metabolism of a number of drugs in the intestine. Celiac disease results in small intestinal atrophy. We hypothesized that this would result in a loss of CYP3A.

AB - Cytochrome P450 (CYP) 3A is constitutively expressed in human intestinal villi and may account for significant "first-pass" prehepatic metabolism of a number of drugs in the intestine. Celiac disease results in small intestinal atrophy. We hypothesized that this would result in a loss of CYP3A.

U2 - 10.1016/S0009-9236(96)90022-3

DO - 10.1016/S0009-9236(96)90022-3

M3 - Article

C2 - 8549032

SN - 0009-9236

VL - 59

SP - 41

EP - 46

JO - Clinical Pharmacology & Therapeutics

JF - Clinical Pharmacology & Therapeutics

IS - 1

ER -

Decreased intestinal CYP3A in celiac disease: reversal after successful gluten-free diet: a potential source of interindividual variability in first-pass drug metabolism

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this